OncoMatch/Clinical Trials/NCT07106736
MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma
Is NCT07106736 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including BCMA CAR-T and GPRC5D/CD3 BiTEs for multiple myeloma, newly diagnosed.
Treatment: BCMA CAR-T · GPRC5D/CD3 BiTEs — This is a prospective, single-center, clinical study to evaluate the efficacy and safety of a fully immunotherapy-based strategy guided by MRD-driven dynamic risk stratification in transplant-ineligible patients with newly diagnosed multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA (TNFRSF17) positive (positive)
Tumor cells were BCMA positive
Required: GPRC5D positive (positive)
Tumor cells were GPRC5D positive
Performance status
ECOG 3–4(Completely disabled)
ECOG performance status 3-4
Demographics
Prior therapy
Cannot have received: bcma-targeted therapy
Cannot have received: car-t cell therapy
Lab requirements
Kidney function
creatinine clearance ≥ 30ml/min (cockroft-gault formula)
Liver function
serum total bilirubin <2 x uln, serum ast and alt <3 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07106736 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior bcma-targeted therapy, car-t cell therapy disqualifies patients from enrollment.
Does this trial require TNFRSF17?
Yes, TNFRSF17 positive is a required biomarker for enrollment.
Does this trial require GPRC5D?
Yes, GPRC5D positive is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages